Sirolimus Prophylaxis for aGVHD in TME SCID

Status Withdrawn

Clinical Trial Summary

Study Design: SCID infants receiving an unconditioned haploidentical transplant will be started on Sirolimus (0.05 mg/kg/day) day -5 for Acute Graft-Versus-Host Disease (aGVHD) prophylaxis. Sirolimus levels will be monitored with goal sirolimus trough level of 5-8 ng/mL. Patients will be monitored for signs of aGVHD as defined by UCSF SOP CL 221.06 through day +100. Sirolimus will be tapered once T-regulatory cell to CD4 effector cell ratio is > or = 9%.

Setting: Inpatient BMT Unit Benioff Children's Hospital at UCSF Medical Center

Study Subjects: 15 infants with diagnosis of maternally engrafted T cells SCID by CA Newborn screen receiving unconditioned haploidentical HSCT

Main Outcome Measures: Incidence of aGVHD (dermatitis, hepatitis, enteritis) as defined by SOP CL 221.06 by Day +100.

Hypothesis 1. Patients placed on sirolimus prophylaxis will have lower incidence of aGVHD compared to historical controls.

Hypothesis 2. Lower doses of sirolimus milligram per kilogram will be required to maintain goal troughs of 5-8 ng/mL.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02177760
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Withdrawn
Phase	Phase 2
Start date	July 2014
Completion date	November 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00006335` - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID	N/A
Not yet recruiting	`NCT02231983` - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China	N/A
Active, not recruiting	`NCT03597594` - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Phase 1/Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Completed	`NCT00001255` - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study	N/A
Recruiting	`NCT05651113` - The Experience of Screening for SCID
Completed	`NCT00794508` - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID	Phase 2
Recruiting	`NCT03538899` - Autologous Gene Therapy for Artemis-Deficient SCID	Phase 1/Phase 2
Recruiting	`NCT05298930` - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Completed	`NCT00845416` - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population	N/A
Terminated	`NCT00006054` - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies	N/A
Completed	`NCT03878069` - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting	`NCT01019876` - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases	Phase 2/Phase 3
Completed	`NCT03513328` - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation	Phase 1/Phase 2
Recruiting	`NCT00695279` - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed	`NCT01420627` - EZN-2279 in Patients With ADA-SCID	Phase 3
Terminated	`NCT02127892` - SCID Bu/Flu/ATG Study With T Cell Depletion	Phase 1/Phase 2
Completed	`NCT04246840` - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
Completed	`NCT01529827` - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2